TF
CYCN icon

TimeScale Financial’s Cyclerion Therapeutics CYCN Stock Holding History

TimeScale Financial’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$9 – 634
2022
Q4 		$9 Hold
1
– – ﹤0.01% 590
2022
Q3 		$0 Hold
1
– – ﹤0.01% 552
2022
Q2 		$0 Hold
1
– – ﹤0.01% 527
2022
Q1 		$0 Hold
1
– – ﹤0.01% 530
2021
Q4 		$0 Hold
1
– – ﹤0.01% 520
2021
Q3 		$0 Hold
1
– – ﹤0.01% 513
2021
Q2 		$0 Hold
1
– – ﹤0.01% 516
2021
Q1 		$0 Hold
1
– – ﹤0.01% 515
2020
Q4 		$0 Hold
1
– – ﹤0.01% 442
2020
Q3 		$0 Hold
1
– – ﹤0.01% 466
2020
Q2 		$0 Hold
1
– – ﹤0.01% 452
2020
Q1 		$0 Hold
1
– – ﹤0.01% 431
2019
Q4 		$0 Hold
1
– – ﹤0.01% 517
2019
Q3 		$0 Hold
1
– – ﹤0.01% 504
2019
Q2 		$0 Buy
+1
New +$283 ﹤0.01% 516

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TimeScale Financial's CYCN Position: Q1 2023 in Review

TimeScale Financial sold out of Cyclerion Therapeutics (CYCN) in Q1 2023, closing a stake of 1 share — an estimated $9 sold.

TimeScale Financial first reported a position in CYCN in Q2 2019 and held it in 15 quarters. The position peaked at $9 in Q4 2022. 34 funds tracked by Wall St. Rank hold CYCN as of Q1 2023.

  • TimeScale Financial reported no remaining Cyclerion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TimeScale Financial sold 1 Cyclerion Therapeutics share in Q1 2023, an estimated $9.
  • TimeScale Financial first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 15 quarters.
  • TimeScale Financial's Cyclerion Therapeutics position peaked at $9 in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2023.

Based on TimeScale Financial's 13F filing for Q1 2023, filed 24 Apr 2023.